FDA draft guidance on statistical methods to evaluate similarity between brand-name drugs and biosimilar copies was withdrawn by the agency after it received comments. Pharmaceutical Scientist founder Sarfaraz Niazi submitted a citizen petition asking the agency to waive bridging studies for qualified non-US comparator drugs, encourage payers to cover biosimilars only for new patients and rethink analytical similarity testing protocols.
FDA pulls policy on biosimilar development after comment period
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.